Mantle cell lymphoma (MCL) is clinically characterised by its heterogenous behaviour with
courses ranging from indolent cases that do not require therapy for years to highly …

Cancer cells are disordered by nature and thus featured by higher internal redox level than
healthy cells. Redox imbalance could trigger programmed cell death if exceeded a certain …

Concordant activation of MYC and BCL-2 oncoproteins in double-hit lymphoma (DHL)
results in aggressive disease that is refractory to treatment. By integrating activity-based …

Mitochondria have long been controversial organelles in cancer. Early discoveries in cancer
metabolism placed much emphasis on cytosolic contributions. Initial debate focused on if …

Although outcomes following first-line therapy for patients with indolent or aggressive non-
Hodgkin lymphoma (NHL) are continually improving, relapse is still common. Current …

Intracellular Ca2+ signals control several physiological and pathophysiological processes.
The main tool to chelate intracellular Ca2+ is intracellular BAPTA (BAPTAi), usually …

BCL-2 family proteins are frequently aberrantly expressed in mantle cell lymphoma (MCL).
Recently, the BCL-2-specific inhibitor venetoclax has been approved by the US Food and …

Ibrutinib, a bruton's tyrosine kinase (BTK) inhibitor, provokes robust clinical responses in
aggressive mantle cell lymphoma (MCL), yet many patients relapse with lethal Ibrutinib …

Management of patients with newly diagnosed mantle cell lymphoma (MCL) depends on the
age and fitness of the patient. For younger patients, the commonly accepted standard of care …

Besides many other mutations in known cancer driver genes, mantle cell lymphoma (MCL)
is characterized by recurrent genetic alterations of important regulators of the …